Sagimet Biosciences Inc. (SGMT)

NASDAQ: SGMT · IEX Real-Time Price · USD
5.42
-0.31 (-5.41%)
At close: Mar 28, 2024, 4:00 PM
5.61
+0.19 (3.51%)
After-hours: Mar 28, 2024, 7:49 PM EDT
-5.41%
Market Cap 191.38M
Revenue (ttm) 2.00M
Net Income (ttm) -27.88M
Shares Out 31.90M
EPS (ttm) -2.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,133,734
Open 5.73
Previous Close 5.73
Day's Range 5.35 - 6.05
52-Week Range 2.13 - 20.71
Beta n/a
Analysts Strong Buy
Price Target 41.50 (+665.68%)
Earnings Date Mar 25, 2024

About SGMT

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 14, 2023
Employees 9
Stock Exchange NASDAQ
Ticker Symbol SGMT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for SGMT stock is "Strong Buy." The 12-month stock price forecast is $41.5, which is an increase of 665.68% from the latest price.

Price Target
$41.5
(665.68% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

SAN MATEO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitor...

1 day ago - GlobeNewsWire

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitor...

3 days ago - GlobeNewsWire

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Reported positive topline data from the Phase 2b FASCINATE-2 trial; at week 52 denifanstat met both primary efficacy endpoints and demonstrated statistically significant reduction in fibrosis

4 days ago - GlobeNewsWire

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

SAN MATEO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors...

4 weeks ago - GlobeNewsWire

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

SAN MATEO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibit...

2 months ago - GlobeNewsWire

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

SAN MATEO, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibit...

2 months ago - GlobeNewsWire

Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial of 168 NASH patients with stage 2 or 3 fibrosis -  Primary efficacy endpo...

2 months ago - PRNewsWire

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial of 168 NASH patients with stage 2 or 3 fibrosis

2 months ago - GlobeNewsWire

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

SAN MATEO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors...

4 months ago - GlobeNewsWire

Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit

SAN MATEO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors...

4 months ago - GlobeNewsWire

Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

SAN MATEO, Calif., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors...

4 months ago - GlobeNewsWire

Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

On track to report topline week 52 liver biopsy results from Phase 2b FASCINATE-2 trial with denifanstat in the first quarter of 2024

4 months ago - GlobeNewsWire

Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023

Combination treatment of a FASN inhibitor with semaglutide, a GLP-1 receptor agonist, improved several biomarkers associated with NASH in a mouse model and showed a significant improvement in liver fi...

4 months ago - GlobeNewsWire

Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023

SAN MATEO, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

5 months ago - GlobeNewsWire

Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference

SAN MATEO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that tar...

5 months ago - GlobeNewsWire

Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

SAN MATEO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metaboli...

6 months ago - GlobeNewsWire

Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Completed upsized initial public offering raising $96.4 million in gross proceeds Presented positive data at EASL Congress 2023 from the planned interim readout of the Phase 2b FASCINATE-2 trial in NA...

7 months ago - GlobeNewsWire

Sagimet Biosciences Announces Closing of Underwriters' Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering

SAN MATEO, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunction...

8 months ago - GlobeNewsWire

Sagimet Biosciences Announces Leadership Changes

SAN MATEO, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunction...

9 months ago - GlobeNewsWire

Sagimet Biosciences Announces Pricing of Upsized Initial Public Offering

SAN MATEO, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunction...

9 months ago - GlobeNewsWire

Sagimet Biosciences sets IPO terms, to raise up to about $80 million

Sagimet Biosciences Inc. SGMT, disclosed Monday terms for its initial public offering, in which the California-based biopharmaceutical company focused on developing treatments for nonalcoholic steatoh...

9 months ago - Market Watch

Sagimet Biosciences IPO Registration Document (S-1)

Sagimet Biosciences has filed to go public with an IPO on the NASDAQ.

9 months ago - SEC

Sagimet Biosciences Presents Positive Phase 2b FASCINATE-2 Clinical Trial Interim Data for Denifanstat for the Treatment of NASH at EASL Congress 2023

Denifanstat was well-tolerated and met primary endpoint in planned interim readout with 67% of treated patients achieving ≥30% reductions in liver fat at...

10 months ago - GLOBE NEWSWIRE